[1] Yancy C W , Jessup M , Bozkurt B ,et al.2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure[J].Journal of cardiac failure, 2017, 23(8):1476-1488.DOI:10.1016/j.jacc.2016.05.011.

[2] 中华医学会心血管病学分会，中国医师协会心血管内科医师分会，中国医师协会心力衰竭专业委员会，中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南（2024），中华心血管病杂志，2024 年3 月第 52 卷第 3 期.

[3] 中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 中国心力衰竭基层诊断与治疗指南（2024 年） [J]. 中华全科医师杂志, 2024, 23(6): 1-29. DOI: 10.3760/cma. j.cn114798-20231227-00476.

[4] Christenson RH, Duh SH, Wu AH, et al. Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure. Clin Biochem 2010 May;43(7-8):683-90.

[5] Gabius HJ. Cell surface glycans: the why and how of their functionality as biochemical signals in lectin-mediated information transfer. Crit Rev Immunol 2006;26:43-79.

[6] Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA 2006;103:5060-5.

[7] Kuwabara I, Liu FT. Galectin-3 promotes adhesion of human neutrophils to laminin. J Immunol 1996;156:3939-44.

[8] Liu YH, D'Ambrosio M, Liao TD, et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol 2009;296:H404-12.

[9] Sano H, Hsu DK, Yu L, et al. Human galectin-3 is a novel chemoattractant for monocytes and macrophages. J Immunol 2000;165:2156-64

[3] Sharma U, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004;110:3121-8

[10] de Boer RA, Voors AA, Muntendam P, et al. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009;11:811-7

[11] Whellan DJ, O'Connor CM, Lee KL, et al. HF-ACTION Trial Investigators. Heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION): design and rationale. Am Heart J. 2007 Feb;153(2):201-11

[12] Dumic J, Dabelic S, Flögel M. Galectin-3: an open-ended story. Biochem Biophys Acta 2006;1760:616-635.

[13] Papaspyridonos M, McNeill E, de Bono JP, et al. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol 2008;28:433-440.

[14] Felker GM, Fiuzat M, Shaw LK, et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail 2012;5:72-78.

[15] Lok DJA, Van Der Meer P, Bruggink-André de la Porte PW, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010;99:323-328.

[16] de Boer RA, Lok DJA, Jaarsma T, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011;43:60-68.

[17] van Kimmenade RR, Januzzi JL, Ellinor PT, et al. Utility of aminoterminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006;48(6):1217-1224.

[18] Grandin EW, Jarolim P, Murphy SA, et al. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chem 2012;58(1):267-273.

[19] de Boer RA, van Veldhuisen DJ, Gansevoort RT, et al. The fibrosis marker galectin-3 and outcome in the general population. J Int Med 2011;doi:10.1111/j.1365-2796.2001.02476.x.

[20] Ho J, Liu C, Lyass A, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. Presented at American College of Cardiology 61st Annual Scientific Session & Expo; March 24-27, 2012; Chicago, IL. http://www.abstractsonline. com/EPosterViewer/MediaView.aspx?Ckey=aa93a560-fc3e-4753- 87ae-62527124c28e&wherefrom=topic. Accessed June 6, 2012.

[21] Gullestad L, Ueland T, Kjekshus J, et al. Galectin-3 predicts response to statin therapy in the controlled rosuvastatin multinational trial in heart failure (CORONA). Eur Heart J 2012;doi:10.1093/eurheartj/ehs077.

[22] Primus FJ, Kelley EA, Hansen HJ, et al. “Sandwich”-type immunoassay of carcinoembryonic antigen in patients receiving murine monoclonal antibodies for diagnosis and therapy. Clin Chem 1988;34(2):261-264.

[23] Schroff RW, Foon KA, Beatty SM, et al. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 1985;45(2):879-885.

[25] Boscato LM, Stuart MC. Heterophilic antibodies: a problem for all immunoassays. Clin Chem 1988;34(1):27-33.

[26] Mc MURRAY et al. ESC Committee for Practice Guidelines.ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787-847.

[27] Bui A L , Horwich T B , Fonarow G C .Epidemiology and risk profile of heart failure.[J].Nature Reviews Cardiology, 2011, 8(1):30-41.DOI:10.1038/nrcardio.2010.165.

[28] Creemers, Esther E ,Pinto,et al.Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart.[J].Cardiovascular Research, 2011..

[29] Krzelak A ,Lipińska A.Galectin-3 as a multifunctional protein.[J].Cellular & Molecular Biology Letters, 2004, 9(2):305-328.

[30] Shah R V , Chen-Tournoux A A , Picard M H ,et al.Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure[J].European Journal of Heart Failure, 2014, 12(8):826-832.DOI:10.1093/eurjhf/hfq091.

[31] De Boer R A , Lok D J A , Jaarsma T ,et al.Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction[J].Annals of Medicine, 2011, 43(1):60-68.DOI:10.3109/07853890.2010.538080.

[32] Mccullough P A , Olobatoke A , Vanhecke T E .Galectin-3: a novel blood test for the evaluation and management of patients with heart failure[J].Reviews in Cardiovascular Medicine, 2011, 12(4):200-10.DOI:10.3909/ricm0624.

[33] Basil M Baccouche, Emmajane Rhodenhiser 2, Galectin-3 and HFpEF: Clarifying an Emerging Relationship, Curr Cardiol Rev. 2023 Jul 17;19(5):e200323214796. doi: 10.2174/1573403X1966623032016582.